About Cyclin-dependent kinase 5 activator 1
Cyclin-dependent kinase 5 activator 1 (CDK5R1) is a protein
from Homo sapiens identified by UniProt accession
Q15078, 307 residues long.
MolForge cross-references it against 0 known binders and
129 disease associations.
Target properties
| Protein name | Cyclin-dependent kinase 5 activator 1 |
|---|
| UniProt accession | Q15078 |
|---|
| Gene | CDK5R1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 307 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (129)
Diseases linked to this target (Open Targets).
- Alzheimer disease · score 0.58
- neurodegenerative disease · score 0.40
- attention deficit hyperactivity disorder · score 0.10
- antisocial behaviour measurement · score 0.10
- substance abuse · score 0.10
- emphysema pattern measurement · score 0.09
- PHF-tau measurement · score 0.09
- systolic blood pressure · score 0.09
- hepatocellular carcinoma · score 0.07
- neoplasm · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15078-F1 | alphafold | PREDICTED | 72.96 | — |
Amino-acid sequence (307 residues)
MGTVLSLSPS YRKATLFEDG AATVGHYTAV QNSKNAKDKN LKRHSIISVL PWKRIVAVSA KKKNSKKVQP NSSYQNNITH LNNENLKKSL SCANLSTFAQ PPPAQPPAPP ASQLSGSQTG GSSSVKKAPH PAVTSAGTPK RVIVQASTSE LLRCLGEFLC RRCYRLKHLS PTDPVLWLRS VDRSLLLQGW QDQGFITPAN VVFLYMLCRD VISSEVGSDH ELQAVLLTCL YLSYSYMGNE ISYPLKPFLV ESCKEAFWDR CLSVINLMSS KMLQINADPH YFTQVFSDLK NESGQEDKKR LLLGLDR
Explore Cyclin-dependent kinase 5 activator 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets